Comments
Loading...
Tanvex BioPharma Analyst Ratings and Price Targets | OTC:TANVF | Benzinga
Tanvex BioPharma Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Tanvex BioPharma Corp from these most-recent analyst ratings.
Analyst Ratings for Tanvex BioPharma
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for Tanvex BioPharma (TANVF) stock?
There is no price target for Tanvex BioPharma
What is the most recent analyst rating for Tanvex BioPharma (TANVF)?
There is no analyst for Tanvex BioPharma
When was the last upgrade for Tanvex BioPharma (TANVF)?
There is no last upgrade for Tanvex BioPharma
When was the last downgrade for Tanvex BioPharma (TANVF)?
There is no last downgrade for Tanvex BioPharma.
When is the next analyst rating going to be posted or updated for Tanvex BioPharma (TANVF)?
There is no next analyst rating for Tanvex BioPharma.
Is the Analyst Rating Tanvex BioPharma (TANVF) correct?
There is no next analyst rating for Tanvex BioPharma.
Browse analyst ratings and price targets on all stocks.
